Results 11 to 20 of about 1,959,681 (261)

Guillain–Barre syndrome after antithymocyte globulin administration in a kidney transplant recipient: A case report and literature review

Clinical Case Reports, 2023
Key Clinical Message This report describes a rare case of developing Guillain–Barre syndrome (GBS) following receiving rabbit antithymocyte globulin (ATG) after kidney transplantation to prevent acute allograft rejection in a 34‐year‐old man. The patient
Farnaz Tavakoli, Davood Dalil, Fatemeh Yaghoubi, Seyyed Mohammad Hosseini   +3 more
doaj   +2 more sources

Effectiveness and Safety of Reduced Thymoglobulin Dosing in Low-Risk Kidney Transplant Recipients. [PDF]

J Transplant
Introduction Thymoglobulin, a lymphocyte‐depleting agent, is widely used for induction immunosuppression in kidney transplantation. Despite guideline support, there is no standardized dosing recommendation, resulting in variability across centers. In April 2022, our institution reduced its institutional practice thymoglobulin dose from 4.5 to 3 mg/kg ...
Wazwaz E, Joiner N.
europepmc   +2 more sources

Bioimaging of alloantigen-stimulated regulatory T cells in rat vascularized composite allotransplantation. [PDF]

PLoS ONE, 2018
BACKGROUND:Tipping the balance toward regulatory T cells (Tregs) through adoptive cell therapy has shown promise to induce transplantation tolerance. Although such strategy has been explored in many mice organ transplantation studies, less knowledge was ...
Hui-Yun Cheng, Sheri K L Tay, Chih-Jen Wen, Chih-Fan Lin, Aline Yen-Ling Wang, Ling-Yi Shih, Shiao-Chin Liu, Eiji Kobayashi, Cheng-Hung Lin, Fu-Chan Wei   +9 more
doaj   +1 more source

Vaccinations in children with hematologic malignancies and those receiving hematopoietic stem cell transplants or cellular therapies

Transplant Infectious Disease, Volume 25, Issue S1, November 2023., 2023
Abstract Children who are immune compromised are uniquely threatened by a higher risk of infections, including vaccine‐preventable diseases (VPDs). Children who undergo chemotherapy or cellular therapies may not have preexisting immunity to VPDs at the time of their treatment including not yet receiving their primary vaccine series, and additionally ...
Kari A Neemann, Alice I Sato
wiley   +1 more source

Enhancement of the antibody response to type 3 pneumococcal polysaccharide in mice treated with antilymphocyte serum.

Journal of Immunology, 1970
Mice treated with antilymphocyte serum (ALS) and immunized with type III pneumococcal polysaccharide (SSS-III) showed a tenfold increase in the number of direct splenic plaque-forming cells (PFC); no indirect PFC were detected in such mice.
P. Baker, R. Barth, P. Stashak, D. F. Amsbaugh   +3 more
semanticscholar   +1 more source

Safety and efficacy of one and two booster doses of SARS‐CoV‐2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial

Transplant Infectious Disease, Volume 25, Issue 5, October 2023., 2023
Sequential administration of two booster doses of SARS‐CoV‐2 mRNA vaccine is safe and significantly increases seroconversion rate (SARS‐CoV‐2 IgG ≥10 AU/ml) compared to one booster dose in kidney transplant recipients who remained without a positive humoral response after the previous two‐dose vaccination schedule. Abstract Background Kidney transplant
Petr Drenko, Martin Kacer, Lukas Kielberger, Tomas Vlas, Ondrej Topolcan, Radek Kucera, Tomas Reischig   +6 more
wiley   +1 more source

Tongue necrosis as a manifestation of immune dysfunction: A complex case of systemic lupus erythematosus, histoplasmosis, and macrophage activation syndrome

Clinical Case Reports, Volume 11, Issue 7, July 2023., 2023
Photograph of left sided tongue necrosis present on hospital admission. Key Clinical Message Immune dysfunction can manifest in unexpected ways. We present the case of a patient with systemic lupus erythematosus (SLE) in whom the first sign of disseminated histoplasmosis and consequent macrophage activation syndrome (MAS) was tongue necrosis.
Madalyn Walsh, Alick Feng, Petar Lenert, Bharat Kumar   +3 more
wiley   +1 more source

Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients

Clinical Transplantation, Volume 37, Issue 6, June 2023., 2023
Abstract Background The frequency and significance of cytomegalovirus (CMV) infection in seropositive (R+) heart transplant recipients (HTR) is unclear, with preventative recommendations mostly extrapolated from other groups. We evaluated the incidence and severity of CMV infection in R+ HTR, to identify risk factors and describe outcomes.
Bradley J. Gardiner, Jessica P. Bailey, Mia A. Percival, Beth A. Morgan, Victoria M. Warner, Sue J. Lee, C. Orla Morrissey, David M. Kaye, Anton Y. Peleg, Andrew J. Taylor   +9 more
wiley   +1 more source

Anti‐thymocyte globulin induction with delayed introduction of tacrolimus preserves renal function in pediatric liver transplant recipients

Pediatric Transplantation, Volume 27, Issue 4, June 2023., 2023
Abstract Background Tacrolimus (TAC)‐mediated renal disease occurs in up to 70% of pediatric liver transplant (LT) recipients. The safety and efficacy of renal‐sparing immunosuppression using anti‐thymocyte globulin (ATG) induction and delayed TAC administration has not been studied in children.
Michael E. Rogers, Teresa Ambrosino, Laura Hatcher, Alex Bondoc, Greg Tiao, Anna L. Peters   +5 more
wiley   +1 more source

Tacrolimus rescue therapy for renal allograft rejection - Five-year experience [PDF]

, 1997
Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of
Demetris, AJ, Fung, JJ, Gritsch, HA, Jordan, ML, McCauley, J, McMichael, J, Naraghi, R, Randhawa, P, Scantlebury, VP, Shapiro, R, Smith, D, Starzl, TE, Vivas, CA   +12 more
core   +1 more source